The filing confirms the closing of a divestiture that was previously announced. With no deal value disclosed, the financial impact on Standard BioTools is unclear. Monitor upcoming quarterly filings for the effect on revenue and margins, and watch for updates on the pending Treeline merger and Mass Cytometry sale.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $0.6108entry
- T+1 · 13d ago +0.85%α −0.80% · $0.6160
- T+5 · 7d ago +8.87%α +9.46% · $0.6650
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Standard BioTools completed the previously announced sale of its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The business will operate as a standalone entity named Biomark Scientific. No financial terms of the transaction were disclosed in the filing.
Key Facts
- Standard BioTools closed the sale of its Microfluidics business to ARCHIMED on November 3, 2026.
- The business will operate as a standalone entity named Biomark Scientific.
- No financial consideration or deal terms were disclosed in the filing.
- The filing also references pending transactions: a merger with Treeline Biosciences and the sale of its Mass Cytometry business to Element Biosystems.
Financial Impact
No financial terms disclosed; the sale removes a business line but its contribution to revenue and earnings is not stated.
Risk Factors
- No financial terms were disclosed, making it impossible to assess the materiality of the divestiture.
- The filing references other pending transactions (Treeline merger, Mass Cytometry sale) that introduce execution and regulatory risk.
- The company is undergoing significant restructuring, which could lead to operational disruption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-041705 |
| Document: ef20084814_ex99-1.htm | 0001140361-26-041705 |
| Document: 0001140361-26-041705-index-headers.html | 0001140361-26-041705 |
| Document: 0001140361-26-041705-index.html | 0001140361-26-041705 |
| Document: 0001140361-26-041705.txt | 0001140361-26-041705 |
Track record
23 reports on LAB
7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +17.95% at T+20 after the Feb 24, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today 425 Neutral 4/10 Entry price pending
- Nov 16, 2026today 8-K Neutral 3/10 Entry price pending
- Nov 3, 202613d ago 425 Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago 8-K Neutral 4/10 Viewing Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $0.6108 to $0.6160 Now $0.6200 +1.51% ▲ +0.85% −0.80% vs SPY
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $0.6400 to $0.6056 Now $0.6200 −3.12% ▼ −5.38% −4.85% vs SPY
- Oct 21, 202626d ago S-4/A Bearish 7/10 Entry $0.6500 to $0.6400 Now $0.6200 +4.62% ▲ +1.54% +0.36% vs SPY
- Oct 9, 20265w ago S-4/A Neutral 6/10 Entry $0.6578 to $0.6589 Now $0.6200 −5.75% ▲ +0.17% +0.18% vs SPY
- Oct 5, 20266w ago 425 Neutral 5/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $0.7220 to $0.6787 Now $0.6200 −14.13% ▼ −6.00% −5.76% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers